Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Differential Effects of Influenza Virus NA, HA Head, and HA Stalk Antibodies on Peripheral Blood Leukocyte Gene Expression during Human Infection.

Walters KA, Zhu R, Welge M, Scherler K, Park JK, Rahil Z, Wang H, Auvil L, Bushell C, Lee MY, Baxter D, Bristol T, Rosas LA, Cervantes-Medina A, Czajkowski L, Han A, Memoli MJ, Taubenberger JK, Kash JC.

MBio. 2019 May 14;10(3). pii: e00760-19. doi: 10.1128/mBio.00760-19.

2.

Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.

Gao J, Couzens L, Burke DF, Wan H, Wilson P, Memoli MJ, Xu X, Harvey R, Wrammert J, Ahmed R, Taubenberger JK, Smith DJ, Fouchier RAM, Eichelberger MC.

MBio. 2019 Apr 9;10(2). pii: e00307-19. doi: 10.1128/mBio.00307-19.

3.

Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and "Universal" Vaccine Development.

Memoli MJ, Han A, Walters KA, Czajkowski L, Reed S, Athota R, Rosas LA, Cervantes-Medina A, Park JK, Morens DM, Kash JC, Taubenberger JK.

Clin Infect Dis. 2019 Apr 6. pii: ciz281. doi: 10.1093/cid/ciz281. [Epub ahead of print]

PMID:
30953061
4.

A Dose Finding Study of a Wild-Type Influenza A/H3N2 virus in a Healthy Volunteer Human Challenge Model.

Han A, Czajkowski LM, Donaldson A, Baus HA, Reed SM, Athota RS, Bristol T, Rosas LA, Cervantes-Medina A, Taubenberger JK, Memoli MJ.

Clin Infect Dis. 2019 Feb 16. pii: ciz141. doi: 10.1093/cid/ciz141. [Epub ahead of print]

PMID:
30770534
5.

Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model.

Han A, Poon JL, Powers JH 3rd, Leidy NK, Yu R, Memoli MJ.

BMC Infect Dis. 2018 Jul 28;18(1):353. doi: 10.1186/s12879-018-3220-8.

6.

Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI).

Powers JH 3rd, Bacci ED, Leidy NK, Poon JL, Stringer S, Memoli MJ, Han A, Fairchok MP, Coles C, Owens J, Chen WJ, Arnold JC, Danaher PJ, Lalani T, Burgess TH, Millar EV, Ridore M, Hernández A, Rodríguez-Zulueta P, Ortega-Gallegos H, Galindo-Fraga A, Ruiz-Palacios GM, Pett S, Fischer W, Gillor D, Moreno Macias L, DuVal A, Rothman R, Dugas A, Guerrero ML.

PLoS One. 2018 Mar 22;13(3):e0194180. doi: 10.1371/journal.pone.0194180. eCollection 2018.

7.

Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients.

Powers JH 3rd, Bacci ED, Guerrero ML, Leidy NK, Stringer S, Kim K, Memoli MJ, Han A, Fairchok MP, Chen WJ, Arnold JC, Danaher PJ, Lalani T, Ridoré M, Burgess TH, Millar EV, Hernández A, Rodríguez-Zulueta P, Smolskis MC, Ortega-Gallegos H, Pett S, Fischer W, Gillor D, Macias LM, DuVal A, Rothman R, Dugas A, Ruiz-Palacios GM.

Value Health. 2018 Feb;21(2):210-218. doi: 10.1016/j.jval.2017.04.014. Epub 2017 Jun 7.

8.

Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.

Park JK, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Rosas LA, Cervantes-Medina A, Taubenberger JK, Memoli MJ.

MBio. 2018 Jan 23;9(1). pii: e02284-17. doi: 10.1128/mBio.02284-17.

9.

Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.

Hunsberger S, Memoli MJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02018-17. doi: 10.1128/AAC.02018-17. Print 2018 Jan. No abstract available.

10.

Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Kash JC, Walters KA, Kindrachuk J, Baxter D, Scherler K, Janosko KB, Adams RD, Herbert AS, James RM, Stonier SW, Memoli MJ, Dye JM, Davey RT Jr, Chertow DS, Taubenberger JK.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaai9321. doi: 10.1126/scitranslmed.aai9321.

11.

IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity.

Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R, Ravetch JV.

Science. 2017 Jan 27;355(6323):395-398. doi: 10.1126/science.aai8128.

12.

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.

Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT Jr, Taubenberger JK.

MBio. 2016 Apr 19;7(2):e00417-16. doi: 10.1128/mBio.00417-16.

13.

Critically ill patients with H7N9: new virus, old challenges*.

Memoli MJ.

Crit Care Med. 2015 Feb;43(2):487-8. doi: 10.1097/CCM.0000000000000776. No abstract available.

14.

Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.

Memoli MJ, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K, Fargis S, Stein M, Dunfee RL, Shaw PA, Davey RT, Taubenberger JK.

Clin Infect Dis. 2015 Mar 1;60(5):693-702. doi: 10.1093/cid/ciu924. Epub 2014 Nov 20.

15.

Glycosylation, hypogammaglobulinemia, and resistance to viral infections.

Sadat MA, Moir S, Chun TW, Lusso P, Kaplan G, Wolfe L, Memoli MJ, He M, Vega H, Kim LJY, Huang Y, Hussein N, Nievas E, Mitchell R, Garofalo M, Louie A, Ireland DC, Grunes C, Cimbro R, Patel V, Holzapfel G, Salahuddin D, Bristol T, Adams D, Marciano BE, Hegde M, Li Y, Calvo KR, Stoddard J, Justement JS, Jacques J, Priel DAL, Murray D, Sun P, Kuhns DB, Boerkoel CF, Chiorini JA, Di Pasquale G, Verthelyi D, Rosenzweig SD.

N Engl J Med. 2014 Apr 24;370(17):1615-1625. doi: 10.1056/NEJMoa1302846. Epub 2014 Apr 9.

16.

The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts.

Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, Hagey R, Voell J, Fiorentino C, Ademposi A, Shoham S, Taubenberger JK.

Clin Infect Dis. 2014 Jan;58(2):214-24. doi: 10.1093/cid/cit725. Epub 2013 Nov 1.

17.

Pandemic research in the ICU: always be prepared.

Memoli MJ.

Crit Care Med. 2013 Apr;41(4):1147-8. doi: 10.1097/CCM.0b013e31827c0605. No abstract available.

18.

Bacterial coinfection in influenza: a grand rounds review.

Chertow DS, Memoli MJ.

JAMA. 2013 Jan 16;309(3):275-82. doi: 10.1001/jama.2012.194139.

PMID:
23321766
19.

Influenza in pregnancy.

Memoli MJ, Harvey H, Morens DM, Taubenberger JK.

Influenza Other Respir Viruses. 2013 Nov;7(6):1033-9. doi: 10.1111/irv.12055. Epub 2012 Nov 21. Review.

20.

In vivo evaluation of pathogenicity and transmissibility of influenza A(H1N1)pdm09 hemagglutinin receptor binding domain 222 intrahost variants isolated from a single immunocompromised patient.

Memoli MJ, Bristol T, Proudfoot KE, Davis AS, Dunham EJ, Taubenberger JK.

Virology. 2012 Jun 20;428(1):21-9. doi: 10.1016/j.virol.2012.02.018.

21.

Obese mice have increased morbidity and mortality compared to non-obese mice during infection with the 2009 pandemic H1N1 influenza virus.

Easterbrook JD, Dunfee RL, Schwartzman LM, Jagger BW, Sandouk A, Kash JC, Memoli MJ, Taubenberger JK.

Influenza Other Respir Viruses. 2011 Nov;5(6):418-25. doi: 10.1111/j.1750-2659.2011.00254.x. Epub 2011 Apr 18.

22.

Detection of seasonal H3N2 influenza A virus by type-specific TaqMan minor groove binder probe assay.

Wang R, Schwartzman LM, Memoli MJ, Taubenberger JK.

Diagn Microbiol Infect Dis. 2011 Jun;70(2):281-4. doi: 10.1016/j.diagmicrobio.2011.01.012. Epub 2011 Mar 22.

23.

Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets.

Memoli MJ, Davis AS, Proudfoot K, Chertow DS, Hrabal RJ, Bristol T, Taubenberger JK.

J Infect Dis. 2011 Feb 1;203(3):348-57. doi: 10.1093/infdis/jiq067. Epub 2010 Dec 20.

24.

pH1N1 influenza A: timing is everything.

Memoli MJ.

Crit Care Med. 2010 Oct;38(10):2081-2. doi: 10.1097/CCM.0b013e3181ee4061. No abstract available.

25.

The PB2-E627K mutation attenuates viruses containing the 2009 H1N1 influenza pandemic polymerase.

Jagger BW, Memoli MJ, Sheng ZM, Qi L, Hrabal RJ, Allen GL, Dugan VG, Wang R, Digard P, Kash JC, Taubenberger JK.

MBio. 2010 May 18;1(1). pii: e00067-10. doi: 10.1128/mBio.00067-10.

26.

Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus.

Kash JC, Qi L, Dugan VG, Jagger BW, Hrabal RJ, Memoli MJ, Morens DM, Taubenberger JK.

Influenza Other Respir Viruses. 2010 May 1;4(3):121-7. doi: 10.1111/j.1750-2659.2010.00132.x.

27.

Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host.

Memoli MJ, Hrabal RJ, Hassantoufighi A, Jagger BW, Sheng ZM, Eichelberger MC, Taubenberger JK.

J Infect Dis. 2010 May 1;201(9):1397-403. doi: 10.1086/651610.

28.

Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.

Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK.

Clin Infect Dis. 2010 May 1;50(9):1252-5. doi: 10.1086/651605.

29.

The 1918 influenza pandemic: lessons for 2009 and the future.

Morens DM, Taubenberger JK, Harvey HA, Memoli MJ.

Crit Care Med. 2010 Apr;38(4 Suppl):e10-20. doi: 10.1097/CCM.0b013e3181ceb25b. Review.

30.

Recent human influenza A/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift.

Memoli MJ, Jagger BW, Dugan VG, Qi L, Jackson JP, Taubenberger JK.

J Infect Dis. 2009 Oct 15;200(8):1232-41. doi: 10.1086/605893.

31.

An early 'classical' swine H1N1 influenza virus shows similar pathogenicity to the 1918 pandemic virus in ferrets and mice.

Memoli MJ, Tumpey TM, Jagger BW, Dugan VG, Sheng ZM, Qi L, Kash JC, Taubenberger JK.

Virology. 2009 Oct 25;393(2):338-45. doi: 10.1016/j.virol.2009.08.021. Epub 2009 Sep 5.

32.

Pandemic and seasonal influenza: therapeutic challenges.

Memoli MJ, Morens DM, Taubenberger JK.

Drug Discov Today. 2008 Jul;13(13-14):590-5. doi: 10.1016/j.drudis.2008.03.024. Epub 2008 May 15. Review.

Supplemental Content

Loading ...
Support Center